Video Experimental Relacionado
Updated: Jul 21, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Prevención de la broncoconstricción inducida por el ejercicio mediante la inhalación de frusemida
S Bianco1, A Vaghi, M Robuschi
1Institute of Lung Disease, University of Siena, Italy.
Lancet (London, England)
|July 30, 1988
Resumen
La frusemida inhalada previene eficazmente la broncoconstricción inducida por el ejercicio en pacientes con asma. Este diurético muestra un efecto protector relacionado con la dosis cuando se inhala, a diferencia de la administración oral.
Área de la Ciencia:
- Medicina Pulmonar La medicina pulmonar es el tratamiento de las enfermedades pulmonares.
- Farmacología Farmacología.
Sus antecedentes:
- La broncoconstricción inducida por el ejercicio (EIB, por sus siglas en inglés) es una afección común en pacientes con asma.
- La hipótesis de hiperosmolaridad sugiere que la deshidratación de las vías respiratorias contribuye al BEI.
Objetivo del estudio:
- Investigar la eficacia de la frusemida inhalada en la prevención de EIB.
- Para comparar la frusemida inhalada con la frusemida oral y el placebo para la prevención de la EIB.
Principales métodos:
- Se realizó un estudio en tres partes, aleatorizado, doble ciego, controlado con placebo.
- Se incluyeron pacientes asmáticos con al menos un 20% de caída del FEV1 después del ejercicio.
- La frusemida inhalada (14 mg y 28 mg) y la frusemida oral (20 mg) se probaron con el placebo.
Principales resultados:
- La frusemida inhalada demostró un efecto protector significativo, dependiendo de la dosis, contra la EIB.
- La caída promedio porcentual máxima en FEV1 se redujo sustancialmente con frusemida inhalada en comparación con el placebo.
- La frusemida oral no mostró ningún efecto protector significativo contra la EIB.
Conclusiones:
- La frusemida inhalada es efectiva para prevenir la broncoconstricción inducida por el ejercicio en el asma.
- Los hallazgos apoyan la hipótesis de hiperosmolaridad del BEI.
- La frusemida inhalada puede ofrecer una nueva estrategia terapéutica para la gestión de la EIB.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...